What is QuidelOrtho Corporation's JPAC — R&D?

QuidelOrtho Corporation (QDEL) reported JPAC — R&D of $300K in Q1 2026.

How has QuidelOrtho Corporation's JPAC — R&D changed year-over-year?

QuidelOrtho Corporation's JPAC — R&D decreased by 25.0% year-over-year, from $400K to $300K.

What does JPAC — R&D mean?

Refers to the expenditures dedicated to the innovation, design, and clinical validation of new diagnostic technologies within the JPAC segment. This investment is critical for maintaining long-term competitiveness and expanding the segment's product portfolio.

QuidelOrtho Corporation QDEL JPAC — R&D

Other segment segments

China

$700K-22.2%

Latin America

$500K+25.0%

EMEA

$400K-33.3%

North America

$400K0.0%

Similar metrics at other companies

KLICAPS — R&D

$2.92M+12.1%

BRCAmericas & Asia — R&D

$16.95M+27.3%

GENAcquired in-process research and development

$10M—

RUMAcquired in-process research and development

$5.74M+19.9%

SYREAcquired in-process research and development

$30M—

AMLXAMX0035PSP — Research And Development Expense Excluding Acquired In Process Cost

$649K-85.8%

Other financials

Income statement

See full

Revenue$619.8M-10.5%

Gross profit$263.8M-23.2%

Operating income-$31.8M-198%

Net income-$91.8M-623%

EPS (diluted)-$1.35-611%

Balance sheet

See full

Cash & equivalents$140.4M+10.4%

Total debt$3.1B+0.3%

Total equity$1.9B-38.2%

Total assets$5.6B-12.9%

Cash flow

See full

Operating cash flow-$33.0M-150%

CapEx$34.0M-39.5%

Free cash flow-$67.0M-813%

Valuation

See full

Market cap$832.61M-51.4%

Enterprise value$3.8B-20.1%

P/S0.3×-0.3×

Profitability

See full

Gross margin45%-2.0pp

Operating margin-37%-46.2pp

Net margin-45.6%-75.7pp

FCF margin13.8%—

Returns & leverage

See full

Return on equity-49.9%-70.8pp

Debt / equity1.7×+0.6×

Current ratio1.4×+0.2×

Where this comes from

Reported directly by QuidelOrtho Corporation in its filing.

Tagged under the XBRL concept qdel:SegmentInformationResearchAndDevelopmentExpense.

The official record: QuidelOrtho Corporation’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about QuidelOrtho Corporation's jpac — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is QuidelOrtho Corporation's JPAC — R&D?: QuidelOrtho Corporation (QDEL) reported JPAC — R&D of $300K in Q1 2026.
How has QuidelOrtho Corporation's JPAC — R&D changed year-over-year?: QuidelOrtho Corporation's JPAC — R&D decreased by 25.0% year-over-year, from $400K to $300K.
What does JPAC — R&D mean?: Refers to the expenditures dedicated to the innovation, design, and clinical validation of new diagnostic technologies within the JPAC segment. This investment is critical for maintaining long-term competitiveness and expanding the segment's product portfolio.